Susquehanna Fundamental Investments’s KalVista Pharmaceuticals KALV Stock Holding History

Susquehanna Fundamental Investments’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-10,686	Closed	-$130K	–	638
2025 Q3	$130K	Sell	10,686 -18,198	-63%	-$251K	0.01%	531
2025 Q2	$327K	Sell	28,884 -14,259	-33%	-$174K	0.01%	608
2025 Q1	$498K	Sell	43,143 -37,176	-46%	-$379K	0.01%	843
2024 Q4	$680K	Buy	+80,319	New	+$832K	0.01%	797
2024 Q2	$807K	Buy	68,526 +52,347	+324%	+$611K	0.02%	597
2024 Q1	$192K	Buy	+16,179	New	+$216K	0.01%	624
2021 Q4	–	Sell	-23,871	Closed	-$417K	–	1611
2021 Q3	$417K	Sell	23,871 -5,686	-19%	-$115K	0.01%	1284
2021 Q2	$708K	Sell	29,557 -11,010	-27%	-$288K	0.01%	1019
2021 Q1	$1.04M	Buy	40,567 +11,600	+40%	+$305K	0.02%	873
2020 Q4	$550K	Buy	+28,967	New	+$497K	0.01%	1066

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Susquehanna Fundamental Investments's KALV Position: Q4 2025 in Review

Susquehanna Fundamental Investments sold out of KalVista Pharmaceuticals (KALV) in Q4 2025, closing a stake of 10,686 shares — an estimated $130K sold.

Susquehanna Fundamental Investments first reported a position in KALV in Q4 2020 and held it in 10 quarters. The position peaked at $1.04M in Q1 2021. 161 funds tracked by Wall St. Rank hold KALV as of Q4 2025.

Susquehanna Fundamental Investments reported no remaining KalVista Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Susquehanna Fundamental Investments sold 10,686 KalVista Pharmaceuticals shares in Q4 2025, an estimated $130K.
Susquehanna Fundamental Investments first reported a position in KalVista Pharmaceuticals in Q4 2020 and held it in 10 quarters.
Susquehanna Fundamental Investments's KalVista Pharmaceuticals position peaked at $1.04M in Q1 2021.
161 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q4 2025.

Based on Susquehanna Fundamental Investments's 13F filing for Q4 2025, filed 17 Feb 2026.